NCT02437604View on ClinicalTrials.gov

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

September 30, 2015

Conditions
Asthma
Interventions
DRUG

Treatment A: Fp MDPI

Fp MDPI 200 mcg, 1 inhalation

DRUG

Treatment B: FS MDPI

FS MDPI 200/12.5 mcg, 1 inhalation

DRUG

Treatment C Flovent

FLOVENT DISKUS 250 mcg, 2 inhalations

DRUG

Treatment D: Advair

ADVAIR DISKUS 500/50 mcg, 1 inhalation

Trial Locations (3)

Unknown

Teva Investigational Site 13178, Raleigh

Teva Investigational Site 13177, Edmond

Teva Investigational Site 13179, San Antonio

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02437604 - Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older | Biotech Hunter | Biotech Hunter